Issues
Synthesis and preliminary in vivo studies of radiopharmaceuticals based on metallocomplexes of technetium-99m radionuclide with somatostatin analogues
«Radiation and Risk», 2025, vol. 34, No. 3, pp.18-29
DOI: 10.21870/0131-3878-2025-34-3-18-29
Authors
Tishchenko V.K. – Head of Lab., D. Sc., Biol. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: +7(910)522-50-72; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .Fedorova A.V. – Sen. Researcher, C. Sc., Biol.
Ryzhikova T.P. – Lead. Engineer
Chibisova O.F. – Researcher
Stepchenkova E.D. – Jun. Researcher
Belkina S.V. – Lead. Researcher, C. Sc., Biol.
Tsishnatti N.A. – Lab. Assistant
Shcherbakova A.N. – Engineer
Vlasova O.P. – Lead. Researcher, C. Sc., Biol.
Minaeva N.G. – Lead. Researcher, C. Sc., Biol.
Ivanov S.A. – Director, Corr. Member of RAS, MD, Prof. of RUDN University Dep. A. Tsyb MRRC.
Morozova N.B. – Sen. Researcher, C. Sc., Biol. P. Hertsen MORI.
1 A. Tsyb MRRC, Obninsk
2 NMRRC, Obninsk
3 P. Hertsen MORI, Moscow
4 Peoples' Friendship University of Russia named after Patrice Lumumba, Moscow
Abstract
Neuroendocrine tumors are heterogeneous group of malignant neoplasms, originating from neuro-endocrine cells. Their key feature is the overexpression of somatostatin receptors, which can serve as molecular targets and provide the possibility of radiopharmaceuticals (RPs) targeting. The use of synthetic peptide-based somatostatin analogues RPs, labelled with technetium-99m (99mTc), allows to determine the localization of the primary tumor focus and metastasis, and also to monitor the response of treatment with subsequent observation of disease recurrence. The aim of this study was to synthesize 99mTc-HYNIC-TOC and 99mTc-HYNIC-TATE metal complexes and to evaluate their biodistribution in vivo. The metal complexes 99mTc-HYNIC-TOC and 99mTc-HYNIC-TATE were synthesized using EDDA and tricine as co-ligands with heating to 95 oC and adding of tin chloride SnCl2·2H2O. The radiochemical purity of 99mTc-HYNIC-TOC and 99mTc-HYNIC-TATE was higher than 90%. A single intravenous injection of metal complexes in mice with transplanted SK-Mel-28 xenografts demonstrated increased accumulation of both RPs in tumor as compared with majority of organs and tissues, except kidneys. The uptake of 99mTc-HYNIC-TOC and 99mTc-HYNIC-TATE in kidneys were 1.366-49.637 %/g and 4.797-46.661 %/g, respectively. No statistically significant differences in 99mTc-HYNIC-TOC and 99mTc-HYNIC-TATE accumulation in organs and tissues were observed. The obtained results demonstrate the possibility of further RPs application for neuroendocrine tumors imaging.
Key words
somatostatin analogs, technetium-99m, neuroendocrine tumors, somatostatin receptors, HYNIC-TOC, HYNIC-TATE, radiopharmaceutical, somatostatin receptor scintigraphy, laboratory mice, radiobiology, nuclear medicine.
References
1. Slashchuk K.Yu., Rumyantsev P.O., Degtyarev M.V., Serzhenko S.S., Baranova O.D., Trukhin A.A., Sirota Ya.A. Molecular imaging of neuroendocrine tumors by somatostatin-receptor scintigraphy (SPECT/CT) with 99mTc-Tektrotyd. Meditsinskaya radiologiya i radiatsionnaya bezopasnost’ – Medical Radiology and Radiation Safety, 2020, vol. 65, no. 2, pp. 44-49. (In Russian).
2. Rabinovich E.Z., Savchenko A.Yu., Sukhov V.Yu., Perelygin V.V. Aspects of the problem of clinical trials of modern targeted radiopharmaceuticals. Formuly farmatsii – Pharmacy Formulas, 2022, vol. 4, no. 3, pp. 27-42. (In Russian).
3. Boschi A., Uccelli L., Martini P. A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging. Appl. Sci., 2019, vol. 9, no. 12, pp. 2526. DOI: 10.3390/app9122526.
4. Tishchenko V.K., Vlasova O.P., Ivanov S.A., Kaprin A.D. Radiopharmaceuticals based on somatostatin analogs and technetium-99m radionuclide for diagnosis of neuroendocrine tumors: a literature review. Meditsinskaya radiologiya i radiatsionnaya bezopasnost’ – Medical Radiology and Radiation Safety, 2025, vol. 70, no. 1, pp. 93-101. (In Russian).
5. Besyadovskiy R.A., Ivanov K.V., Kozyura A.K. A reference guide for radiobiologists. Moscow, Atomizdat, 1978. 128 p. (In Russian).
6. Von Guggenberg E., Mikolajczak R., Janota B., Riccabona G., Decristoforo C. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-oc-treotide, a somatostatin analog for tumor diagnosis. J. Pharm. Sci., 2004, vol. 93, no. 10, pp. 2497-2506.
7. Gandomkar M., Najafi R., Babaei M.H., Shafei M., Ebrahimi S. Synthesis, development and preclinical comparison of two new peptide based freeze-dried kit formulation 99mTc-EDDA-Tricine-HYNIC-TOC and 99mTc-EDDA-Tricine-HYNIC-TATE for somatostatin receptor positive tumor scintigraphy. DARU, 2006, vol. 14, no. 4, pp. 183-189.
8. Shinto A.S., Kamaleshwaran K., Vyshak K., Sudhakar N., Banerjee S., Korde A., Samuel G., Mallia M. Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating gastro-entero pancreatic neuro endocrine tumours. Asia Ocean. J. Nucl. Med. Biol., 2014, vol. 2, no. 1, pp. 30-41.
9. De K., Banerjee I., Misra M. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation. Amino Acids, 2015, vol. 47, pp. 1135-1153.
10. Mukherjee A., Korde A., Shinto A., Sarma H.D., Kamaleswaran K., Dash A. Studies on batch formulation of a freeze dried kit for the preparation of 99mTc-HYNIC-TATE for imaging neuroendocrine tumors. Appl. Radiat. Isot., 2019, vol. 145, pp. 180-186.
11. Kaihani S., Sadeghzadeh N. Study of the 99mTc-labeling conditions of 6-hydrazinonicotinamide-conjugated peptides from a new perspective: Introduction to the term radio-stoichiometry. J. Labelled Comp. Radiopharm., 2020, vol. 63, no. 14, pp. 582-596.
12. Meszaros L., Dose A., Biagini S.C.G., Blower P. Hydrazinonicotinic acid (HYNIC) – coordination chemistry and applications in radiopharmaceutical chemistry. Inorg. Chim. Acta, 2020, vol. 363, no. 6, pp. 1059-1069.
13. Evans B.J., King A.T., Katsifis A., Matesic L., Jamie J.F. Methods to enhance the metabolic stability of peptide-based PET radiopharmaceuticals. Molecules, 2020, vol. 25, no. 10, pp. 2314. DOI: 10.3390/mole-cules25102314.
14. Milewska-Kranc A., Cwikła J.B., Kolasinska-Cwikła A. The role of receptor-ligand interaction in somatosta-tin signaling pathways: implications for neuroendocrine tumors. Cancers, 2024, vol. 16, pp. 116. DOI: 10.3390/cancers16010116.
15. Harris P.E., Zhernosekov K. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Front. Endocrinol. (Lausanne), 2022, vol. 13, pp. 941832. DOI: 10.3389/fendo.2022.941832.
16. Al-Toubah T., Sikaria D., Jesurajan J., Bottiglieri S., Smith J., Pellé E., Hutchinson T., Strosberg J., El-Haddad G. Comparison of nausea and vomiting associated with amino acid formulations coinfused with peptide receptor radionuclide therapy: commercial parenteral nutrition formulas versus compounded argi-nine/lysine. Pancreas, 2021, vol. 50, no. 4, pp. 513-515.
17. Bodei L., Cremonesi M., Zoboli S., Grana C., Bartolomei M., Rocca P., Caracciolo M., Mäcke H.R., Chi-nol M., Paganelli G. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur. J. Nucl. Med. Mol. Imaging, 2003, vol. 30, no. 2, pp. 207-216.
18. Ravera S., Nicola J.P., De Simone G.S., Sigworth F.J., Karakas E., Amzel L.M., Bianchet M.A., Carrasco N. Structural insights into the mechanism of the sodium/iodide symporter. Nature, 2022, vol. 612, no. 7941, pp. 795-801.
19. Petriev V.M., Tishchenko V.K., Koptyaeva K.V., Smoryzanova O.A., Skvortsov V.G. The pharmacokinet-ics of technetium-99m-labelled N,N,N’,N’-ethylenediaminetetra-kis-(methylenephosphonic acid) in intact rats. Khimico-farmatsevticheskiy zhurnal – Pharmaceutical Chemistry Journal, 2015, vol. 49, no. 5, pp. 287-291. (In Russian).
Full-text article (in Russian)